The CDC says that the number of people in the US who have been infected with diseases carried by mosquitoes, ticks, and flea bites have more than tripled in recent years.
The researchers built a combination nucleic acid-antibody test for the disease using an approach they said could be generally useful for rapid test development.
Rheonix has won an administrative supplement to an existing SBIR grant to develop the Zika test using its CARD cartridge and Encompass Optimum platform.
The firm's dual assay for host antigen to HIV as well as viral RNA was described in a proof-of-principle study earlier this year.
The Ithaca, New York-based firm will use the financing to ramp up commercialization of its molecular diagnostic testing platforms.
The firm is aiming at in vitro diagnostics, applied markets, and next-generation sequencing sample preparation.
The Phase II grant will provide the company with funding to develop a commercial-ready version of the test.
The fully automated self-confirming assay will simultaneously detect HIV/AIDS antibodies and viral RNA in a single specimen.
HandyLab has been awarded
Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.
According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.
In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.
CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.